NCT02791269View on ClinicalTrials.gov

A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Peginterferon alfa-2a

180 mcg SC injection QW for 48 weeks.

Trial Locations (6)

8011

Riccarton, Christchurch

Unknown

Auckland

Hamilton

New Plymouth

Rotorua

Whangarei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02791269 - A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program | Biotech Hunter | Biotech Hunter